Pridopidine is still a mess in latest Huntington’s study, but Teva maps PhIII
Six years ago a Danish company called NeuroSearch enjoyed a few days in the sun when it said its experimental drug for Huntington’s diease, Huntexil (pridopidine), had scored positive data for improving motor functions in patients in a Phase III study. But a few weeks later the company was battered by a reassessment of the data, which concluded that the drug had failed.
NeuroSearch never recovered from that setback. But Teva in-licensed the drug. And this week it unveiled new Phase II data on Huntexil, which continues to perform unevenly in clinical studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.